A small number of rationally designed treatments are being developed for mitochondrial disorders [29], including nucleoside substrate enhancement therapy designed specifically for TK2 deficiency [4]. This evidence concerns the gene TK2 and hyperinsulinemic hypoglycemia, familial, 4.